CN106606477A - Sanguisorba aglycone emulsion for injection and preparing method and use thereof - Google Patents
Sanguisorba aglycone emulsion for injection and preparing method and use thereof Download PDFInfo
- Publication number
- CN106606477A CN106606477A CN201610887961.8A CN201610887961A CN106606477A CN 106606477 A CN106606477 A CN 106606477A CN 201610887961 A CN201610887961 A CN 201610887961A CN 106606477 A CN106606477 A CN 106606477A
- Authority
- CN
- China
- Prior art keywords
- parts
- aglycon
- radix sanguisorbae
- emulsion
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a sanguisorba aglycone emulsion for injection; the emulsion is a preparation prepared from the following raw materials and auxiliary materials: sanguisorba aglycone, oil for injection, an emulsifier, glycerol and water. Experimental results indicate that after the preparation prescription makes sanguisorba aglycone into the emulsion for injection, the emulsion for injection can significantly improve the number of peripheral blood leukocytes, neutrophils, erythrocytes, platelets, hemoglobins and bone marrow hematopoietic stem cells, and has obvious effects of treatment and/or prevention of myelosuppression.
Description
Technical field
The present invention relates to a kind of Radix Sanguisorbae aglycon injectable emulsion and preparation method thereof, purposes, belong to field of medicaments.
Background technology
Bone marrow depression is clinically common disease of hematopoietic system, and it can betide the radiation of each system tumor disease and control
Treat and (or) chemotherapy, ionizing radiation cause radiation injury, viral hepatitis, piconaviruses infection or medicine (chloromycetin,
Benzene, sulfanilamide, anti-insane carbuncle medicine, tranquilizer, antithyroid drug, antidiabetic drug, malaria, sleeping pill) etc. factor.Bone marrow depression can
Cause the damage of bone marrow microenvironment, hematopoietic stem cell, hematopoietic cell growth factor etc., grain, red, megakaryocytic series unification system, two
It is or three is that cell is suppressed.Agranulocytosises can cause severe infections；Erythrocyte is significantly reduced and can cause severe anemia；Blood is little
Plate is decreased obviously and causes severe haemorrhage, even results in death.
At present, effectively treatment handss are still lacked for the bone marrow depression that bone marrow depression, especially chemicotherapy cause clinically
Section.Therefore, search out effective medicine to alleviate bone marrow depression, become a problem demanding prompt solution.
Radix Sanguisorbae aglycon is from Rosaceae Radix Sanguisorbae platymiscium Radix Sanguisorbae (Sanguisorba officinalis L.) or comes into leaves ground
In the root of elm [S.officinalis L.var.longifolia (Bertol.) Yu et Li] extract obtain one kind activity into
Point, it is the aglycon of Ziyuglycoside I and Ziyuglycoside I I, chemical name：3 β, -12 alkene -28- carboxylic acids of 19 Alpha-hydroxy ursol, its structural formula
It is as follows：
However, so far there is not yet prepare injectable emulsion as active component with Radix Sanguisorbae aglycon, for treating and/or preventing bone
The open report that marrow suppresses.
The content of the invention
To solve the above problems, the invention provides a kind of Radix Sanguisorbae aglycon injectable emulsion, it is by following supplementary material systems
Standby preparation：Radix Sanguisorbae aglycon, oil for injection, emulsifying agent, glycerol, water.
Further, it is the preparation being prepared from by the supplementary material of following weight proportioning：0.5～10 part of Radix Sanguisorbae aglycon,
Oil for injection 1-300 parts, emulsifying agent 0.5-30 parts, glycerol 1-10 parts, water 1-100 parts.
Further, it is the preparation being prepared from by the supplementary material of following weight proportioning：1 part of Radix Sanguisorbae aglycon, injection
300 parts of oil, 20 parts of emulsifying agent, 8 parts of glycerol, 50 parts of water.
Further, described oil for injection is soybean oil, Medium-chain Triglycerides, fish oil, olive oil, ethyl oleate or castor
One or more mixture in Oleum Sesami；Described emulsifying agent is Egg Yolk Lecithin (PC-98T) or the one kind or two in soybean phospholipid
Kind.
Further, it is the preparation being prepared from by the supplementary material of following weight proportioning：1 part of Radix Sanguisorbae aglycon, soybean oil
300 parts, 20 parts of soybean phospholipid, 8 parts of glycerol, 50 parts of water.
Further, it also includes 0.5～5 part of stabilizer, and the stabilizer is selected from sodium salt or Oleic acid.
Present invention also offers the preparation method of aforesaid injectable emulsion, comprises the steps：
A, the Radix Sanguisorbae aglycon, oil for injection and the emulsifying agent that weigh each weight proportion, add ethanol dissolving；
The ethanol solution that b, concentration are obtained according to a steps, stirring is lower to add glycerol, water；
C, shearing, homogenizing, sterilizing are obtained final product.
Present invention also offers said injector Emulsion is used for the use of the medicine for preparing treatment and/or preventing bone marrow depression
On the way.
Further, described medicine is the purposes for treating and/or preventing the medicine of bone marrow depression caused by chemical substance.
Further, described medicine is to raise peripheral blood leucocyte, neutrophilic granulocyte, erythrocyte, platelet, blood red egg
The medicine of one or more quantity in white or marrow hemopoietic stem cells.
Test result indicate that, Radix Sanguisorbae aglycon is prepared into after injectable emulsion according to invention formulation prescription, significantly can be carried
The quantity of high peripheral blood leucocyte, neutrophilic granulocyte, erythrocyte, platelet, hemoglobin and marrow hemopoietic stem cells, with bright
Aobvious treatment and/or the effect of prevention bone marrow depression.
Obviously, the above of the invention, according to the ordinary technical knowledge and customary means of this area, without departing from
Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification of other various ways can also be made, is replaced or is changed.
The specific embodiment of form, remakes further specifically to the above of the present invention by the following examples
It is bright.But this scope for being interpreted as above-mentioned theme of the invention should not be only limitted to Examples below.It is all based on the above of the present invention
The technology realized belongs to the scope of the present invention.
Description of the drawings
The each experimental mice marrow hemopoietic stem cells of Fig. 1 are counted and are compared.
Specific embodiment
Raw material, equipment used in the specific embodiment of the invention is known product, is obtained by buying commercially available prod.
The preparation of 1 injectable emulsion of the present invention of embodiment
Prescription one (A)：Radix Sanguisorbae aglycon 1g, soybean oil 300g, Egg Yolk Lecithin (PC-98T) 20g, glycerol 8g, water 3500mL.
Prescription two (B)：Radix Sanguisorbae aglycon 2g, Medium-chain Triglycerides 100g, Egg Yolk Lecithin (PC-98T) 20g, glycerol 10g, water 7000mL.
Prescription three (C)：Radix Sanguisorbae aglycon 3g, fish oil 200g, Egg Yolk Lecithin (PC-98T) 30g, glycerol 10g, water 10500mL.
Prescription four (D)：Radix Sanguisorbae aglycon 0.5g, olive oil 300g, Egg Yolk Lecithin (PC-98T) 30g, glycerol 10g, water 1750mL.
Prescription five (E)：Radix Sanguisorbae aglycon 6g, ethyl oleate 300g, Egg Yolk Lecithin (PC-98T) 30g, glycerol 10g, water 21000mL.
Prescription six (F)：Radix Sanguisorbae aglycon 8g, Oleum Ricini 300g, Egg Yolk Lecithin (PC-98T) 30g, glycerol 10g, water 28000mL.
Prescription seven (G)：Radix Sanguisorbae aglycon 10g, soybean oil 300g, soybean phospholipid 30g, glycerol 10g, water 350000mL.Prepare
Method：
Radix Sanguisorbae aglycon is mixed with oils and fatss and phospholipid by recipe quantity, dissolved with ethanol, decompression rotary evaporation removes ethanol,
Under high-speed stirred, Oleic acid and glycerol (Radix Sanguisorbae aglycon are added according to recipe quantity：Oleic acid 1:0.5) with, adding water in Emulsion suspension
The concentration of elm aglycon be 0.3mg/mL, high speed shear 5min under 10000rpm, high pressure homogenize 4 times under 800bar pressure, high pressure goes out
Bacterium, obtains final product.
Beneficial effects of the present invention are proved below by way of specific experiment.
Experimental example 1 prepares the quality evaluation of Radix Sanguisorbae aglycon Emulsion using different auxiliary material
9 experimental grouies of this Setup Experiments.Radix Sanguisorbae aglycon 1.0g, oil phase as shown in table 1, emulsifying agent, stabilizer are taken respectively
With isoosmotic adjusting agent, then by Radix Sanguisorbae aglycon, oil phase and emulsifying agent according to weight proportion be 1:300:20 mixing, it is molten with ethanol
Solution, decompression rotary evaporation remove ethanol, Ding Ji ︰ isoosmotic adjusting agent for 1 according to weight proportion Radix Sanguisorbae Gan Yuan ︰ Wen:0.5:1 high-speed stirring
Lower addition stabilizer, isoosmotic adjusting agent are mixed, the concentration for adding water to Radix Sanguisorbae aglycon in Emulsion is 0.3mg/mL, under 10000rpm at a high speed
Shearing 5min, high pressure homogenize 4 times, autoclaving under 800bar pressure.Observation outward appearance whether there is layering, flocculation, viscous wall, determines particle diameter
Size, determines Ke (with trap A before and after the centrifugation of spectrophotometry EmulsionoStability constant Ke=(A is calculated further with Ao-
A)/Ao× 100%.Ke values are less, illustrate dispersion phase oil droplet float under the action of the centrifugal force or sink it is fewer, the Emulsion is more steady
It is fixed), the results are shown in Table 1.
The quality evaluation result of 1 Radix Sanguisorbae aglycon Emulsion of table
Note："+" is indicated；"-" indicate without；Compare with other groups：*P<0.05
Experimental result：The supplementary product kind according to used by invention formulation prescription, can prepare the preferable Radix Sanguisorbae of quality
Aglycon Emulsion, Emulsion outward appearance is without phenomenons such as layering, flocculation, viscous walls；Wherein, the grain of the Emulsion compared with other experimental grouies of experimental group 6
Footpath, Ke values have significance to reduce (P<0.05), show that the supplementary product kind that preparation Radix Sanguisorbae aglycon Emulsion optimum is used is：Oleum Glycines are
Oil phase, soybean phospholipid are emulsifying agent, and Oleic acid is stabilizer, and glycerol is osmotic pressure regulator.
Impact of 2 supplementary product consumption of experimental example to Radix Sanguisorbae aglycon Emulsion quality
7 experimental grouies of this Setup Experiments.Weight proportion as shown in table 2 weighs Radix Sanguisorbae aglycon, Oleum Glycines, soybean phospholipid respectively
(fixed Radix Sanguisorbae aglycon weight 0.6g), is dissolved with ethanol, and decompression rotary evaporation removes ethanol, according to weight proportion Radix Sanguisorbae glycosides unit ︰
You Suan ︰ glycerol is 1:0.5:Oleic acid, glycerol are added under 1 high-speed stirred, the concentration for adding water to Radix Sanguisorbae aglycon in Emulsion is 0.3mg/
High speed shear 5min under mL, 10000rpm, high pressure homogenize 4 times, autoclaving under 800bar pressure.Observation outward appearance whether there is layering,
Flocculation, viscous wall, determine size, determine Ke, the results are shown in Table 2.
The quality evaluation result of 2 Radix Sanguisorbae aglycon Emulsion of table
Note："+" is indicated；"-" indicate without；Compare with other groups：*P<0.05
Experimental result：Radix Sanguisorbae aglycon：Oleum Glycines：Soybean phospholipid weight proportion is 1:1～350:In the range of 0.5～40,
The preferable Emulsion of quality can be prepared；Wherein, experimental group 6 particle diameter of Emulsion, Ke values compared with other experimental grouies has significance
Reduce (P<0.05) the optimum amount proportioning for, showing adjuvant in Radix Sanguisorbae aglycon Emulsion is：Radix Sanguisorbae aglycon：Oleum Glycines：Soybean phospholipid=
1:300:20。
The effect experiment of 3 Radix Sanguisorbae aglycon Emulsion of the present invention of experimental example
1. experiment material, reagent, instrument
1.1st, Radix Sanguisorbae aglycon fat emulsion solution group (A, B, C, D, E, F, G) of test medicine different auxiliary material preparation, Radix Sanguisorbae glycosides
First 10%DMSO- physiological saline groups.
1.2nd, tool drug cyclophosphamide.
1.3rd, laboratory animal KM- mice：18.5～22.5g.
1.4th, experimental apparatus：Full-automatic blood cell analysis machine；BS-600L electronic balances：Specification：600g/0.1g, Shanghai friend's sound
Weighing apparatus company limited.
2nd, statistical method
Statistical analysiss are carried out with 17.0 softwares of SPSS.Data are with mean ± standard deviationRepresent, between group, adopt Dan Yin
Plain variance analyses, carry out LSD inspections between the neat person's group of variance, heterogeneity of variance person carries out Tamhane ' s T2 inspections.
3rd, experimental technique
3.1, laboratory animal packet and model prepare
All Animal adaptabilities are randomly divided into by body weight after feeding 1 week：Blank group；Model group；Different prescription Radix Sanguisorbae aglycons
Emulsion group (A, B, C, D, E, F, G), is configured to 2.5mgkg-1 suspensions, prepared before use；Radix Sanguisorbae aglycon group：Radix Sanguisorbae aglycon
Powder, uses 10%DMSO- physiological saline solutions, is configured to 2.5mgkg-1 suspensions, prepared before use.Test the 1st day, remove
Outside blank group, remaining each group mice presses 50mgkg-1 dosage intraperitoneal injection of cyclophosphamide normal saline solutions, for three days on end, empty
White group mouse tail vein injection equal-volume normal saline.
3.2nd, it is administered
Each experimental group from test the 1st day start according to dosage, iv give relative medicine, blank group and model group mouse tail vein
Injection equal-volume normal saline, continuous 7 days.
3.3rd, collection of specimens
Test the 8th day, each experimental mice eye socket takes blood, collect to be measured with the 0.5mlEP pipes equipped with EDTA anticoagulant.
3.4, Testing index and method
(1) peripheral hemogram detection：Using full-automatic blood counting instrument to each experimental mice peripheral blood leucocyte (WBC),
Neutrophilic granulocyte (NEUT) erythrocyte (RBC), platelet (PLT), hemoglobin (HGB) are counted.
(2) marrow hemopoietic stem cells count dense with bovine serum albumin is contained (with medullary cell CD34+ antigen presentation gauge)
Spend and right side of mice femur bone marrow cell is gone out for 0.2% PBS, take out 106 cell centrifugations, abandon supernatant, add 30 μ
L Normal Mouse Serums add the rat anti-mouse CD34+ antibody of 10 μ L FITC labellings to close unspecific binding sites, right
The corresponding control antibodies of 10 μ L of addition are looked after, 4 DEG C of lucifuges react 30min.2mL erythrocyte cracked liquids are added, 5min is acted on, is washed cell
2 times, the PI dye liquors of final concentration of 3 μ g/mL are added, using flow cytomery medullary cell CD34+ antigen presentations.
4th, experimental result
4.1st, peripheral blood major blood cell is counted and is compared
As shown in Table 3, compare with model group, different auxiliary material prepare Radix Sanguisorbae aglycon Emulsion group mouse peripheral blood WBC, RBC,
PLT quantity has significantly raise (P<0.05), there was no significant difference for Radix Sanguisorbae aglycon group；Compare with Radix Sanguisorbae aglycon group, different auxiliary material
Radix Sanguisorbae aglycon injectable emulsion group mouse peripheral blood WBC, RBC, PLT quantity processed has significantly raise (P<0.05).
3 each experimental mice peripheral blood hemocyte quantity of table
Note：Compare with model group, * P<0.05, * * P<0.01；Note：Compare with Radix Sanguisorbae aglycon group,△P<0.05,△△P<
0.01。
As shown in Table 4, compare with model group, injection Radix Sanguisorbae aglycon Emulsion group mouse peripheral blood prepared by different auxiliary material
NEUT and HGB quantity has significantly raise (P<0.05), there was no significant difference for Radix Sanguisorbae aglycon group；Compare with Radix Sanguisorbae aglycon group, no
The injection Radix Sanguisorbae aglycon Emulsion group mouse peripheral blood NEUT and HGB quantity prepared with prescription has significantly raise (P<0.05).
4 each experimental mice peripheral blood NEUT and HGB quantity of table
Note：Compare with model group, * P<0.05, * * P<0.01；Compare with Radix Sanguisorbae aglycon group,△P<0.05,△△P<0.01。
4.2nd, marrow hemopoietic stem cells are counted and are compared
From fig. 1, it can be seen that comparing with model group, different prescription Radix Sanguisorbae aglycon Emulsion group mouse hematopoietic stem cell quantity have
(P is raised significantly<0.05), there was no significant difference for Radix Sanguisorbae aglycon group；Compare with Radix Sanguisorbae aglycon group, different auxiliary material Radix Sanguisorbae aglycon breast
Agent group mouse hematopoietic stem cell quantity has significantly raise (P<0.05).
Above test result indicate that, Radix Sanguisorbae aglycon is prepared into after injectable emulsion according to invention formulation prescription, can be shown
The effect for improving medicine hemocytes increasing level is write, bone marrow depression can be effectively prevented and treated.
Claims (10)
1. a kind of Radix Sanguisorbae aglycon injectable emulsion, is characterized in that：It is the preparation being prepared from by following supplementary materials：Radix Sanguisorbae glycosides
Unit, oil for injection, emulsifying agent, glycerol, water.
2. injectable emulsion as claimed in claim 1, is characterized in that：It is prepared from by the supplementary material of following weight proportioning
Preparation：0.5～10 part of Radix Sanguisorbae aglycon, oil for injection 1-300 parts, emulsifying agent 0.5-30 parts, glycerol 1-10 parts, water 1-100 parts.
3. injectable emulsion as claimed in claim 2, is characterized in that：It is prepared from by the supplementary material of following weight proportioning
Preparation：1 part of Radix Sanguisorbae aglycon, 300 parts of oil for injection, 20 parts of emulsifying agent, 8 parts of glycerol, 50 parts of water.
4. the injectable emulsion as described in claim 1-3 any one, is characterized in that：Described oil for injection be soybean oil,
One or more mixture in Medium-chain Triglycerides, fish oil, olive oil, ethyl oleate or Oleum Ricini；Described breast
Agent is one or two in Egg Yolk Lecithin (PC-98T) or soybean phospholipid.
5. the injectable emulsion as described in claim 1-4 any one, is characterized in that：It is by the former auxiliary of following weight proportioning
The preparation that material is prepared from：1 part of Radix Sanguisorbae aglycon, 300 parts of soybean oil, 20 parts of soybean phospholipid, 8 parts of glycerol, 50 parts of water.
6. the injectable emulsion as described in claim 1-5 any one, is characterized in that：It also stablizes comprising 0.5～5 part
Agent, the stabilizer are selected from sodium salt or Oleic acid.
7. a kind of preparation method of the injectable emulsion described in claim 1-6 any one, is characterized in that：Including following step
Suddenly：
A, the Radix Sanguisorbae aglycon, oil for injection and the emulsifying agent that weigh each weight proportion, add ethanol dissolving；
The ethanol solution that b, concentration are obtained according to a steps, stirring is lower to add glycerol, water；
C, shearing, homogenizing, sterilizing are obtained final product.
8. the injectable emulsion described in claim 1-6 any one is used to prepare treatment and/or prevents the medicine of bone marrow depression
Purposes.
9. purposes as claimed in claim 8, is characterized in that：Described medicine be treat and/or prevent chemical substance caused by
The purposes of the medicine of bone marrow depression.
10. purposes as claimed in claim 8 or 9, is characterized in that：Described medicine is to raise peripheral blood leucocyte, neutral grain
The medicine of one or more quantity in cell, erythrocyte, platelet, hemoglobin or marrow hemopoietic stem cells.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510673470 | 2015-10-16 | ||
| CN2015106734709 | 2015-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106606477A true CN106606477A (en) | 2017-05-03 |
Family
ID=58614929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610887961.8A Pending CN106606477A (en) | 2015-10-16 | 2016-10-11 | Sanguisorba aglycone emulsion for injection and preparing method and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106606477A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018133111A1 (en) * | 2017-01-23 | 2018-07-26 | 四川英路维特医药科技有限公司 | Ziyuglycogenin emulsion for injection, preparation method therefor and use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593436A (en) * | 2003-09-08 | 2005-03-16 | 成都地奥制药集团有限公司 | Application of ursane type triterpenoid saponin in the preparing process of leucocyte and/or platelet increasing medicine |
| CN101036643A (en) * | 2006-03-13 | 2007-09-19 | 海南盛科天然药物研究院有限公司 | Pharmaceutical composition containing arctigenin and preparation method |
| JP2014234346A (en) * | 2013-05-30 | 2014-12-15 | 耕平 山下 | Hair treatment agent |
-
2016
- 2016-10-11 CN CN201610887961.8A patent/CN106606477A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593436A (en) * | 2003-09-08 | 2005-03-16 | 成都地奥制药集团有限公司 | Application of ursane type triterpenoid saponin in the preparing process of leucocyte and/or platelet increasing medicine |
| CN101036643A (en) * | 2006-03-13 | 2007-09-19 | 海南盛科天然药物研究院有限公司 | Pharmaceutical composition containing arctigenin and preparation method |
| JP2014234346A (en) * | 2013-05-30 | 2014-12-15 | 耕平 山下 | Hair treatment agent |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018133111A1 (en) * | 2017-01-23 | 2018-07-26 | 四川英路维特医药科技有限公司 | Ziyuglycogenin emulsion for injection, preparation method therefor and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bessman et al. | Improved classification of anemias by MCV and RDW | |
| EP0981379B1 (en) | Artificial bodily fluid | |
| PL182890B1 (en) | Nigella sativa as a therapeutic agent | |
| Ness et al. | Tn polyagglutination preceding acute leukemia | |
| DE2635065C2 (en) | Process for the semi-continuous treatment of whole blood for the production of biologically active hematopoietic chalon extracts | |
| CN108403834A (en) | A kind of Herba Houttuyniae volatile oil Liposomal formulation and its preparation method and application | |
| CN106606477A (en) | Sanguisorba aglycone emulsion for injection and preparing method and use thereof | |
| Maxwell | Production of a Heinz body anaemia in the domestic fowl after ingestion of dimethyl disulphide: a haematological and ultrastructural study | |
| CN106551906A (en) | A kind of sanguisorbin II emulsions and preparation method thereof | |
| CN106580881A (en) | Sanguisorba officinalis aglycone lipidosome, and preparation method and purpose thereof | |
| Medici et al. | Influence of transfusions on the erythropoietic-stimulating factor (ESF) of anemic patients | |
| Epstein et al. | The in vivo induction of mouse lymphocyte transformation by phytohemagglutinin | |
| CN106606479A (en) | Ziyuglycoside I emulsion and preparation method thereof | |
| CN109589367A (en) | A kind of vine tea general flavone solid lipid nano granule and preparation method | |
| CN106551907A (en) | II liposome of a kind of sanguisorbin and preparation method thereof | |
| CN106606474A (en) | 3beta, 19alpha-hydroxy-urs-12-en-28-carboxylic acid injection, and preparation method and applications thereof | |
| CN106606504A (en) | Garden burnet root sapogenin hydroxypropyl [beta]-cyclodextrin clathrate and preparation method and application thereof | |
| WO2018133111A1 (en) | Ziyuglycogenin emulsion for injection, preparation method therefor and use thereof | |
| CN106580884A (en) | Garden burnet sapogenin solid dispersion as well as preparation method and application thereof | |
| CN106606478A (en) | Sanguisorba officinalis sapogenin oral emulsion as well as preparation method and applications thereof | |
| CN106551905A (en) | A kind of Ziyuglycoside I I Orally taken emulsion and its production and use | |
| CN106580882A (en) | Ziyuglycoside I lipidosome and preparation method thereof | |
| WO2018133108A1 (en) | Ziyuglycoside ii emulsion and preparation method therefor | |
| CN106606480A (en) | Ziyu-glycoside I oral emulsion and preparation method thereof | |
| CN116211901B (en) | Method for preparing brucea javanica oil composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170503 |
|
| RJ01 | Rejection of invention patent application after publication |